The year in cardiology: Heart failure 2014

European Heart Journal

Volumn 36, Issue 7, 2015, Pages 421-424a

  Voors, Adriaan A ^a   Ruschitzka, Frank ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FERRIC CARBOXYMALTOSE; IRON; MINERALOCORTICOID ANTAGONIST; PLACEBO; SACUBITRIL PLUS VALSARTAN; SERELAXIN; SPIRONOLACTONE; CARDIOTONIC AGENT; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ACUTE HEART FAILURE; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOLOGY; CARDIOVASCULAR MORTALITY; EPIGENETICS; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IRON DEFICIENCY; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; REMOTE SENSING; TELEMONITORING; VAGUS NERVE STIMULATION; CARDIAC RESYNCHRONIZATION THERAPY; DRUG EFFECTS; FORECASTING; HEART STROKE VOLUME; INTRAVENOUS DRUG ADMINISTRATION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TELEMEDICINE; TRENDS; UTILIZATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOTONIC AGENTS; EPIGENOMICS; FORECASTING; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RELAXIN; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; STROKE VOLUME; TELEMEDICINE; VAGUS NERVE STIMULATION;

EID: 84935098062     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu503     Document Type: Note

References (19)

1. McMurray JJ, Packer M, Desai AS, Gong J, LefkowitzMP, RizkalaARet al. Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371: 993-1004.
2. Voors AA, Dorhout B, van der Meer P. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs 2013;22: 1041-1047.
3. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2014; doi:10.1093/eurheartj/ehu385.
4. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, DrexlerHet al. Ferric carboxymaltose in patients with heart failure and iron deficiency.NEngl J Med 2009;361:2436-2448.
5. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014.
6. Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, Daubert JP, Estes NA III, Foster E, Greenberg H, Kautzner J, Klempfner R, Kuniss M, Merkely B, Pfeffer MA, Quesada A, Viskin S, McNitt S, Polonsky B, Ghanem A, Solomon SD, Wilber D, ZarebaW, Moss AJ. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014;370:1694-1701.
7. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for heart failure with preserved ejection fraction.NEngl JMed2014;370:1383-1392.
8. HwangSJ, MelenovskyV, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014;63(25 Pt A): 2817-2827.
9. Mentz RJ, Broderick S, Shaw LK, Fiuzat M, O'Connor CM. Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease). J Am Coll Cardiol 2014;63: 251-258.
10. Santos AB, Kraigher-Krainer E, Bello N, Claggett B, Zile MR, Pieske B et al. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J 2014;35:42-47.
11. McMurray JJ,Adamopoulos S, Anker SD, Auricchio A,BohmM, DicksteinKet al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14: 803-869.
12. Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet 2014;384:583-590.
13. Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the neural cardiac therapy for heart failure (NECTAR-HF) randomized controlled trial. Eur Heart J 2014; doi:10.1093/eurheartj/ehu345.
14. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, GreenbergBH et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAXAHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.
15. Ponikowski P, MitrovicV, Ruda M, Fernandez A, Voors AA, Vishnevsky Aet al.Arandomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2014; 35:431-441.
16. Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 2014;35:1041-1050.
17. Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, FilippatosGet al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome-an analysis from RELAX-AHF. Eur J Heart Fail 2014;16:1230-1240.
18. Zsebo K, Yaroshinsky A, Rudy JJ,Wagner K, Greenberg B, JessupMet al. Long-term effects ofAAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 2014;114:101-108.
19. Wahlquist C, Jeong D, Rojas-Munoz A, Kho C, Lee A, Mitsuyama S et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014;508:531-535.